Industry Partnerships

Unravel Biosciences   is a therapeutics company that uses artificial intelligence (AI) models of patient RNA networks followed by rapid in vivo screening and clinical validation of discovered targets to develop new therapeutics. CSNK2A1 Foundation is partnering with Unravel to analyze RNA from OCNDS patient fibroblast samples and the K198R OCNDS mouse model. The award leverages Unravel’s BioNAV™ AI prediction platform to analyze patient mutations and identify the most suitable mouse genetic model through cross-species stratification of drug response. The project will build upon previous work by Unravel in which several drug candidates that proved effective in Unravel’s SquishyWare™ in vivo models were identified.